Introduction
The field of immuno-oncology has revolutionized cancer treatment by harnessing the power of the immune system to fight cancer cells. With the advent of new immunotherapies, a plethora of abbreviations and acronyms have emerged to describe these innovative drugs. This article aims to decode some of the most common abbreviations used in the context of cancer-fighting immunotherapies, providing a comprehensive guide for those navigating the complex landscape of immuno-oncology.
Common Abbreviations in Immuno-Oncology
CAR-T Cells
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy that involves engineering a patient’s own T-cells to recognize and attack cancer cells. The “CAR” in CAR-T cells refers to the chimeric antigen receptor that is genetically inserted into the T-cells.
Example: A patient with acute lymphoblastic leukemia receives a CAR-T cell therapy known as tisagenlecleucel (Kymriah).
PD-1/PD-L1 Inhibitors
Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) inhibitors are a class of immunotherapies that target the PD-1/PD-L1 pathway, which cancer cells use to evade the immune system. By blocking this pathway, these drugs allow the immune system to recognize and attack cancer cells.
Example: Pembrolizumab (Keytruda) and nivolumab (Opdivo) are two examples of PD-1/PD-L1 inhibitors used in the treatment of various cancers.
CTLA-4 Inhibitors
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors work by blocking the activity of CTLA-4, a protein that inhibits the immune response. By inhibiting CTLA-4, these drugs help to unleash the immune system’s ability to attack cancer cells.
Example: Ipilimumab (Yervoy) is a CTLA-4 inhibitor that has been approved for the treatment of melanoma and certain other cancers.
IPIL
Interleukin-2 (IL-2) is a type of cytokine that plays a role in the immune response. IPIL (Interleukin-2) refers to the use of IL-2 as a therapeutic agent, often in combination with other treatments.
Example: IL-2 has been used in the treatment of renal cell carcinoma and melanoma, often in combination with other therapies.
ICIs
Immunotherapy Checkpoint Inhibitors (ICIs) is a broad term that encompasses both PD-1/PD-L1 inhibitors and CTLA-4 inhibitors. These drugs work by releasing the brakes on the immune system, allowing it to attack cancer cells more effectively.
Example: A patient with lung cancer is prescribed an ICI, such as atezolizumab (Tecentriq), to treat their disease.
MMR
Microsatellite Instability (MMR) refers to a genetic instability found in some cancers that can lead to the production of mutations in DNA. MMR-dysfunctional tumors are more likely to respond to immunotherapies.
Example: Immunotherapy may be considered for a patient with MMR-dysfunctional colorectal cancer, such as those with Lynch syndrome.
Nivolumab
Nivolumab (Opdivo) is a PD-1 inhibitor that has been approved for the treatment of various types of cancer, including melanoma, lung cancer, and renal cell carcinoma.
Example: Nivolumab is often used as a first-line treatment for advanced melanoma.
Pembrolizumab
Pembrolizumab (Keytruda) is another PD-1 inhibitor that has been approved for the treatment of multiple types of cancer, including melanoma, lung cancer, and head and neck cancer.
Example: Pembrolizumab is frequently used in the treatment of advanced non-small cell lung cancer (NSCLC).
Conclusion
Understanding the abbreviations and acronyms used in immuno-oncology is crucial for patients, healthcare providers, and researchers alike. By decoding these terms, we can better navigate the complex landscape of cancer-fighting immunotherapies and make informed decisions about treatment options.